First Citizens BancShares
FCNCA
$1976.37
-3.40%
First Citizens BancShares Inc is a financial holding company operating in the regional banking industry. It is a prominent player with a nationwide branch network and a strategic focus on serving technology, healthcare, and innovation firms following its acquisition of Silicon Valley Bank.…
FCNCA
First Citizens BancShares
$1976.37
Investment Opinion: Should I buy FCNCA Today?
Based on a synthesis of the data, the objective assessment is a Hold. The stock's attractive forward P/E of 9.2 and strong free cash flow provide a fundamental floor, suggesting limited downside from current levels. However, near-term headwinds from declining margins, high leverage, and weak price momentum currently outweigh the catalysts for a clear Buy rating. Investors may await more consistent financial performance or a more compelling entry point.
Sign up to view all
FCNCA 12-Month Price Forecast
The analysis leans neutral due to the tension between clear value (low P/E, high FCF) and clear risks (leverage, declining margins). The base case of range-bound trading is most probable.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on First Citizens BancShares's 12-month outlook, with a consensus price target around $2569.28 and implied upside of +30.0% versus the current price.
Average Target
$2569.28
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$1581 - $2569
Analyst target range
Analyst consensus data, such as a specific target price or ratings distribution, is not available in the provided inputs. The institutional ratings show recent actions from several firms, including 'Buy' from TD Cowen and UBS, 'Overweight' from JP Morgan, and 'Hold' or 'Neutral' ratings from others like Truist Securities, Citigroup, and Barclays. However, without a consolidated target price or sufficient quantitative analyst coverage details, a definitive consensus summary cannot be provided.
Bulls vs Bears: FCNCA Investment Factors
FCNCA presents a mixed picture. Its compelling valuation and strong cash flow are offset by recent earnings pressure and high leverage. The stock's significant pullback from highs may have priced in near-term concerns, but execution on its SVB integration is key.
Bullish
- Attractive Valuation Multiples: Forward P/E of 9.2 and P/B of 1.2 are modest, suggesting potential undervaluation.
- Strong Cash Flow Generation: Robust TTM free cash flow of $2.07B supports financial flexibility and shareholder returns.
- Strategic SVB Acquisition: Provides a foothold in high-growth tech, healthcare, and innovation banking segments.
- Below-Market Volatility: Beta of 0.655 indicates historically lower volatility than the broader market.
Bearish
- Recent Revenue and Profit Decline: Q4 revenue down 0.9% YoY; net margin fell from 18.98% to 15.87%.
- Elevated Debt Levels: Debt-to-equity ratio of 1.62 indicates high financial leverage.
- Sharp Price Correction: Stock down 14.5% over 3 months, underperforming the S&P 500.
- Moderate Profitability Metrics: ROE of 9.92% and net margin of 15.2% are solid but not exceptional.
FCNCA Technical Analysis
Overall Assessment: The stock has exhibited significant volatility over the past six months, with a peak of $2232.21 and a recent close of $1847. The 6-month price change is positive at 4.96%, but the stock has retreated sharply from its highs, currently trading 17.3% below its 52-week high. The price is 25.3% above its 52-week low of $1473.62, indicating it remains in the upper half of its annual range.
Short-term Performance: The stock has experienced a sharp correction in the short term. The 1-month price change is -2.69%, and the 3-month change is -14.50%. This recent weakness contrasts with the positive 6-month performance, suggesting a significant pullback from the highs reached in late December 2025.
Current Position: The current price of $1847 sits near the middle of the provided 180-day price data, which ranged from a low near $1638 to a high above $2200. The stock's beta of 0.655 indicates it has been less volatile than the broader market, yet its recent 3-month decline of -14.50% has underperformed the S&P 500's -7.32% drop over the same period.
Beta
0.65
0.65x market volatility
Max Drawdown
-24.1%
Largest decline past year
52-Week Range
$1624-$2232
Price range past year
Annual Return
+11.5%
Cumulative gain past year
| Period | FCNCA Return | S&P 500 |
|---|---|---|
| 1m | +6.4% | +8.5% |
| 3m | -2.0% | +2.8% |
| 6m | +11.3% | +4.6% |
| 1y | +11.5% | +32.3% |
| ytd | -8.4% | +3.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
FCNCA Fundamental Analysis
Revenue & Profitability: Revenue for Q4 2025 was $3.66B, showing a slight year-over-year decline of -0.92% from the prior year's Q4. Net income for the quarter was $580M, resulting in a net margin of 15.87%, which is down from 18.98% in Q4 2024. Quarterly profitability has been inconsistent, with net income fluctuating between $483M and $580M over the past four quarters.
Financial Health: The company's debt-to-equity ratio is elevated at 1.62, indicating a significant reliance on debt financing. However, operating cash flow remains strong, with $1.05B generated in the latest quarter and free cash flow of $720M. The current ratio is 1.03, suggesting adequate short-term liquidity.
Operational Efficiency: Return on Equity (ROE) stands at 9.92%, which is a moderate level of profitability for shareholders. The trailing twelve-month free cash flow is a robust $2.07B. The net margin of 15.22% (from valuation data) reflects solid, though not exceptional, earnings power from its operations.
Quarterly Revenue
$3.7B
2025-12
Revenue YoY Growth
+0.00%
YoY Comparison
Gross Margin
+0.62%
Latest Quarter
Free Cash Flow
$2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is FCNCA Overvalued?
Valuation Level: With a positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E is 12.03, and the forward P/E is 9.19. These multiples suggest the stock is trading at a reasonable valuation relative to its earnings. The Price-to-Book (P/B) ratio is 1.19, indicating the market values the company slightly above its book value.
Peer Comparison: Industry average valuation metrics are not provided in the data for a direct comparison. Based on the provided figures, the forward P/E of 9.2 and P/B of 1.2 appear modest, potentially reflecting market concerns about growth or the banking sector's outlook. The Price-to-Sales (P/S) ratio of 1.83 and EV-to-Sales of 4.43 offer additional context for its sales-based valuation.
PE
12.0x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 0x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.3x
Enterprise Value Multiple
Investment Risk Disclosure
The primary financial risk is the elevated debt-to-equity ratio of 1.62, which increases interest rate sensitivity and financial strain in a downturn. Operational risks include integrating the Silicon Valley Bank acquisition and potential pressure on net interest margins in a shifting rate environment. Market risks are evident in the stock's recent sharp correction (-14.5% in 3 months) and high short interest (short ratio of 5.07), indicating significant bearish sentiment. Furthermore, quarterly results show inconsistent profitability and a slight year-over-year revenue decline, raising questions about near-term growth momentum.
FAQ
Key risks include financial leverage (debt-to-equity of 1.62), integration risks from the Silicon Valley Bank acquisition, and sensitivity to interest rates which can pressure net interest margins. Market-related risks are evident in its recent sharp underperformance (-14.5% over 3 months) and high short interest, indicating significant bearish sentiment.
The 12-month outlook presents a base case target range of $1,750 to $1,950, implying modest upside from the current price near $1,847. The bull case (25% probability) sees a re-test of highs near $2,232, while the bear case (15% probability) could see a decline toward the 52-week low of $1,474. The most likely scenario is range-bound trading as the company navigates current challenges.
The data suggests FCNCA is reasonably valued to slightly undervalued based on earnings. Its forward P/E ratio of 9.2 and Price-to-Book ratio of 1.2 are modest, especially when considering its robust free cash flow generation. However, this valuation likely reflects market concerns about its leverage and growth, meaning it is not deeply undervalued without a fundamental improvement.
Currently, FCNCA is assessed as a Hold, not a strong Buy. While its forward P/E of 9.2 and strong free cash flow are positive, these are counterbalanced by a high debt load (D/E of 1.62) and recent declines in revenue and net margin. The stock may be suitable for value-oriented investors who can tolerate near-term volatility, but it lacks clear near-term catalysts for outperformance.
FCNCA is more suitable for a patient, long-term investment horizon. Its value proposition relies on the successful long-term integration of SVB and steady execution to improve profitability metrics like its 9.92% ROE. The stock's low beta (0.655) and volatility make it less ideal for short-term trading, especially given its recent corrective trend.
